1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Sobi's Doptelet Launch In EU To Drive Transformation

UK Is First EU Market For Commercial Launch

 
• By John Davis

Sobi is launching the thrombocytopenia drug Doptelet in Europe after acquiring the originator, Dova Pharmaceuticals, and expects to capture significant market share from older products while adding to its business in rare diseases, hematology, and immunology.    

Blood cells
• Source: Shutterstock

Swedish Orphan Biovitrum AB (Sobi) is pushing ahead with launching the thrombopoietin receptor agonist, Doptelet (avatrombopag, 20mg tablets), in the EU, part of its drive to transform into a hematology- and immunology-focused rare diseases company with an international footprint. 

Doptelet is indicated in the EU for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

More from Therapy Areas

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.